Amicus Therapeutics (FOLD) Says Data From Phase 3 FACETS Study Published in NEJM
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Amicus Therapeutics (Nasdaq: FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 (FACETS) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat in individuals with Fabry disease were published in the June 9 issue of the New England Journal of Medicine (NEJM). A copy of the manuscript can be found here and in the Science & Technology section of the Amicus Therapeutics corporate website at www.amicusrx.com.
"We are very pleased and honored that the New England Journal of Medicine has published our pivotal Phase 3 FACETS study in treatment-naïve Fabry patients,” said Jay Barth, MD, Chief Medical Officer of Amicus Therapeutics, Inc. “We believe that this study generated a robust data set and validated our precision medicine approach to identify patients with amenable mutations. This Phase 3 study, together with our Phase 3 ERT-switch Study 012, supported the European Commission’s recent full approval for migalastat in the European Union as a first line therapy for Fabry disease in patients 16 years and older who have an amenable genetic mutation. This publication is a significant milestone, and I would like to express my sincerest gratitude to the physicians who were investigators in this study, as well as to the patients and families who participated in the study.”
Prof. Dominique P. Germain, MD, PhD, Division of Medical Genetics at the University of Versailles (Paris-Saclay University) and Assistance Publique - Hôpitaux de Paris stated, “As a treating physician of Fabry disease patients for 15 years, I believe that significant unmet needs remain for these patients. Migalastat is a paradigm of precision medicine with a unique mechanism of action that was developed through a significant patient-centered research effort to first understand the genetics and mutations of the GLA gene underlying this disease and then to identify more than 250 mutations that are amenable to this chaperone therapy. As the lead author of the journal publication along with 40 colleagues from 12 different countries as co-authors, and having served as principal investigator in France for the migalastat clinical studies for the past decade, I believe that migalastat may offer a differentiated and important personalized treatment option for patients with Fabry disease who have an amenable mutation.”
Migalastat is designed to selectively and reversibly bind with high affinity to the active sites of certain mutant forms of alpha-Gal A, the genotypes of which are referred to as amenable mutations (or “suitable” mutations in the NEJM article). As previously announced, the European Commission has granted full approval for migalastat, under the trade name Galafold™, as a first line therapy for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency) and who have an amenable mutation. Amicus is supplying the market in Germany and has commenced the reimbursement processes with healthcare authorities in each of the major European countries.
About FACETS (Study 011)Study 011 was a Phase 3 study designed to measure the reduction of disease substrate (globotriaosylceramide, or GL-3) following treatment with migalastat in Fabry patients with amenable mutations. The study also measured clinical outcomes, including renal function and left ventricular mass index (LVMi), as secondary endpoints. The 24-month study began with a 6-month double-blind, placebo-controlled treatment period, after which all patients were treated with migalastat for a 6-month open-label follow-up period and a subsequent 12-month open-label extension phase. Fabry patients enrolled in Study 011 were naïve to treatment or had not received enzyme replacement therapy (ERT) for at least 6 months prior to study entry. Upon completion, patients were eligible to roll over into a separate extension to continue migalastat.
About Galafold™ and Amenable MutationsGalafold™ (migalastat) is a first-in-class chaperone therapy approved in the EU as a monotherapy for Fabry disease in patients with amenable mutations. Galafold works by stabilizing the body’s own dysfunctional enzyme, so it can clear the accumulation of disease substrate in patients who have amenable mutations. A proprietary in vitro assay (Galafold Amenability Assay) was used to classify more than 800 known GLA mutations as “amenable” or “not amenable” to treatment with Galafold. The current label includes all 269 GLA mutations that have been identified and determined to be amenable based on the Galafold Amenability Assay, which represent between 35% and 50% of the currently diagnosed Fabry population.
Healthcare providers in the EU may access the website www.galafoldamenabilitytable.com to quickly and accurately identify which mutations are categorized as “amenable” or “not amenable” to Galafold. Amicus expects to submit updates to the label as additional GLA mutations are identified and tested in the Galafold Amenability Assay.
Important Safety InformationTreatment with GALAFOLD should be initiated and supervised by specialists experienced in the diagnosis and treatment of Fabry disease. GALAFOLD is not recommended for use in patients with a nonamenable mutation.
- GALAFOLD is not intended for concomitant use with enzyme replacement therapy.
- GALAFOLD is not recommended for use in patients with Fabry disease who have severe renal impairment (<30 mL/min/1.73 m2). The safety and efficacy of GALAFOLD in children 0–15 years of age have not yet been established.
- No dosage adjustments are required in patients with hepatic impairment or in the elderly population.
- There is very limited experience with the use of this medicine in pregnant women. If you are pregnant, think you may be pregnant, or are planning to have a baby, do not take this medicine until you have checked with your doctor, pharmacist, or nurse.
- While taking GALAFOLD, effective birth control should be used. It is not known whether GALAFOLD is excreted in human milk.
- Contraindications to GALAFOLD include hypersensitivity to the active substance or to any of the excipients listed in the PRESCRIBING INFORMATION.
- It is advised to periodically monitor renal function, echocardiographic parameters and biochemical markers (every 6 months) in patients initiated on GALAFOLD or switched to GALAFOLD.
- OVERDOSE: General medical care is recommended in the case of GALAFOLD overdose.
- The most common adverse reaction reported was headache, which was experienced by approximately 10% of patients who received GALAFOLD. For a complete list of adverse reactions, please review the SUMMARY OF PRODUCT CHARACTERISTICS.
- Call your doctor for medical advice about side effects.
For further important safety information for Galafold, including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European SmPC for Galafold available from the EMA website at www.ema.europa.eu.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amicus Therapeutics (FOLD) Announces Positive Prelim. Data from ATB200/AT2221 Phase 1/2 as Paradigm Treatment
- Synergy Pharma (SGYP) Announces Positive Top-Line Results from First Phase 3 Trial of Plecanatide
- Biogen (BIIB), AbbVie (ABBV) Receive Health Canada Approve for Once-Monthly Zinbryata
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!